

## References

---

This is the reference list to the ACE Clinical Guidance "Chronic obstructive pulmonary disease – Diagnosis and management".

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report). Global Initiative for Chronic Obstructive Lung Disease. 2024.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-22.
3. Davies Adeloye PS, Yajie Zhu, Harry Campbell, Aziz Sheikh, Igor Rudan, NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447-58.
4. GBD Compare Data Visualization Seattle, WA: IHME, University of Washington; 2020 [cited 2023 Oct 17]. Available from: <http://vizhub.healthdata.org/gbd-compare>.
5. LaiLeng Woo HES, Sean D Sullivan. The Economic Burden of Chronic Obstructive Pulmonary Disease in the Asia-Pacific Region: A Systematic Review. *Value Health Reg Issues*. 2019;18:121-31.
6. Ministry of Health Singapore. Healthcare utilisation data for patients with COPD. 2023.
7. Graham BL SI, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med*. 2019;200(8):e70-e88.
8. Cooper BG. An update on contraindications for lung function testing. *Thorax*. 2011;66(8):714-23.
9. Clinical Practice Guidelines: Chronic Obstructive Pulmonary Disease. Singapore Ministry of Health. 2017.
10. Yang IA GJ, McDonald CF, McDonald V, Craig S, Goodwin, A, Smith B, McNamara R, Zwar N, Dabscheck E. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2022. 2022.
11. Jiawei Zhou XL, Xingjian Wang, Na Yu, Wei Wang. Accuracy of portable spirometers in the diagnosis of chronic obstructive pulmonary disease A meta-analysis. *NPJ Prim Care Respir Med*. 2022;32(1).
12. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. 2023.
13. Ferguson G, Make B. Stable COPD: Overview of management UpToDate: Wolters Kluwer; 2023 [cited 2023 Nov 24]. Available from: <https://www.uptodate.com>.
14. Jones PW HG, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. *Eur Respir J*. 2009;34(3):648-54.
15. American Thoracic Society. Surveillance for respiratory hazards in the occupational setting. *The American Review of Respiratory Disease*. 1982;126(5):952-6.
16. Hurst JR VJ, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease *N Engl J Med*. 2010;363(12):1128-38.

17. Fletcher C PR. The natural history of chronic airflow obstruction. *Br Med J.* 1977;1(6077):1645-48.
18. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel Liaisons and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. *Am J Prev Med.* 2008;35(2):158-76.
19. American Academy of Family Physicians. Ask and Act Tobacco Cessation Program [cited 2023 Dec 01]. Available from: <https://www.aafp.org/family-physician/patient-care/care-resources/tobacco-and-nicotine/ask-act.html>.
20. Smoking Cessation: Agency for Integrated Care; [cited 2023 Dec 01]. Available from: <https://www.primarycarepages.sg/healthier-sg/care-protocols/preventive-health-care-protocols/smoking-cessation>.
21. Koarai A, Sugiura H, Yamada M, Ichikawa T, Fujino N, Kawayama T, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. *BMC Pulm Med.* 2020;20(1):111.
22. Oba Y KE, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. *Cochrane Database Syst Rev.* 2018;12(12):CD012620.
23. Lipson DA BF, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med.* 2018;378(18):1671-80.
24. Papi A VJ, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2018;391(10125):1076-84.
25. Siddiqui SH GA, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2015;192(4):523-5.
26. Rabe KF MF, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med.* 2020;383(1):35-48.
27. Yang IA CM, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2012;2012(7):CD002991.
28. Landis SH SR, Hilton E, Compton C, Galwey NW. Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink. *COPD.* 2017;14(4):382-8.
29. National Adult Immunisation Schedule: Ministry of Health, Singapore; 2023 [cited 2024 May 09]. Available from: <https://www.moh.gov.sg/resources-statistics/nationally-recommended-vaccines>.
30. Society of Infectious Diseases Singapore, College of Family Physicians Singapore, Chapter of Infectious Disease Physicians. Handbook on Adult Vaccination in Singapore 2020. 2020.
31. Ortega F TJ, Cejudo P, Villagomez R, Sánchez H, Castillo J, Montemayor T. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2002;166(5):669-74.
32. British Thoracic Society Standards of Care Committee. BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. *Thorax.* 2008;i1-i16.

33. Ekström M NF, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. *Ann Am Thorac Soc*. 2015;12(7):1079-92.
34. N. Ambrosino CF. Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases. A narrative review. *Pulmonology*. 2019;25(5):289-98.
35. Vieira PJ CA, Cipriano G Jr, Umpierre D, Arena R, Chiappa GR. Neuromuscular electrical stimulation improves clinical and physiological function in COPD patients. *Respir Med*. 2014;108(4):609-20.
36. Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, et al. Managing Dyspnea in Patients with Advanced Chronic Obstructive Pulmonary Disease: A Canadian Thoracic Society Clinical Practice Guideline. *Canadian Respiratory Journal*. 2011;18:745047.
37. Marchetti N, Lammi MR, Travaline JM, Ciccolella D, Civic B, Criner GJ. Air Current Applied to the Face Improves Exercise Performance in Patients with COPD. *Lung*. 2015;193(5):725-31.